FI953981A - 2-Bentsyyli-polysykliset guaniinijohdannaiset ja menetelmä niiden valmistamiseksi - Google Patents

2-Bentsyyli-polysykliset guaniinijohdannaiset ja menetelmä niiden valmistamiseksi Download PDF

Info

Publication number
FI953981A
FI953981A FI953981A FI953981A FI953981A FI 953981 A FI953981 A FI 953981A FI 953981 A FI953981 A FI 953981A FI 953981 A FI953981 A FI 953981A FI 953981 A FI953981 A FI 953981A
Authority
FI
Finland
Prior art keywords
benzyl
preparation
guanine derivatives
polycyclic guanine
polycyclic
Prior art date
Application number
FI953981A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI953981A0 (fi
Inventor
Deen Tulshian
Brian A Mckittrick
Yan Xia
Samuel Chackalamannil
Dinesh Gala
Donald J Dibenedetto
Max Kugelman
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of FI953981A0 publication Critical patent/FI953981A0/fi
Publication of FI953981A publication Critical patent/FI953981A/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/40Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
FI953981A 1993-02-26 1995-08-24 2-Bentsyyli-polysykliset guaniinijohdannaiset ja menetelmä niiden valmistamiseksi FI953981A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2354993A 1993-02-26 1993-02-26
US2459993A 1993-02-26 1993-02-26
PCT/US1994/001728 WO1994019351A1 (en) 1993-02-26 1994-02-24 2-benzyl-polycyclic guanine derivatives and process for preparing them

Publications (2)

Publication Number Publication Date
FI953981A0 FI953981A0 (fi) 1995-08-24
FI953981A true FI953981A (fi) 1995-08-24

Family

ID=26697306

Family Applications (1)

Application Number Title Priority Date Filing Date
FI953981A FI953981A (fi) 1993-02-26 1995-08-24 2-Bentsyyli-polysykliset guaniinijohdannaiset ja menetelmä niiden valmistamiseksi

Country Status (14)

Country Link
US (1) US5939419A (pt)
EP (1) EP0686157A1 (pt)
JP (1) JPH08507068A (pt)
KR (1) KR960701058A (pt)
CN (1) CN1118600A (pt)
AU (1) AU681875B2 (pt)
CA (1) CA2156918A1 (pt)
FI (1) FI953981A (pt)
HU (1) HUT72640A (pt)
IL (1) IL108754A0 (pt)
NZ (1) NZ262797A (pt)
SG (1) SG43809A1 (pt)
TW (1) TW270118B (pt)
WO (1) WO1994019351A1 (pt)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
AR004752A1 (es) * 1995-11-28 1999-03-10 Schering Corp 2'-[[4'-halo-[1,1'-bifenil]-4-il]metil]-5'-metil-espiro[ciclopentano-1,7' (8'h)-[3h imidazo[2,1-b]purin]-4'(5'h)-onas, uso del mismo para la preparacionde un medicamento, composicion farmaceutica y un proceso para su preparacion.
US5824683A (en) * 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6403799B1 (en) 1999-10-21 2002-06-11 Agouron Pharmaceuticals, Inc. Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
ES2302835T3 (es) * 2001-08-28 2008-08-01 Schering Corporation Inhibidores de fosfodiesterasa v policiclicos de guanina.
EP1790652A1 (en) * 2001-08-28 2007-05-30 Schering Corporation Polycyclic guanine phosphodiesterase V inhibitors
WO2003020702A2 (en) 2001-08-31 2003-03-13 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
JP2005509038A (ja) * 2001-11-09 2005-04-07 シェーリング コーポレイション 多環式グアニン誘導体ホスホジエステラーゼv阻害剤
EP1719772A1 (en) 2002-05-31 2006-11-08 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
ATE363483T1 (de) * 2003-07-31 2007-06-15 Schering Corp Metabolit eines xanthinphosphodiesterase-5- inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen
BRPI0416202A (pt) * 2003-11-21 2006-12-26 Schering Corp formulações inibidoras de fosfodiesterase v
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
US20070004745A1 (en) * 2005-03-25 2007-01-04 Schering-Plough Corporation Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
ES2645371T3 (es) * 2005-06-06 2017-12-05 Intra-Cellular Therapies, Inc. Compuestos orgánicos
EP1919287A4 (en) * 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
CA2632016A1 (en) 2005-12-23 2007-06-28 Astrazeneca Ab Imidazole derivatives for the treatment of gastrointestinal disorders
EP1968947A1 (en) 2005-12-23 2008-09-17 AstraZeneca AB Gaba-b receptor modulators
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US9255099B2 (en) * 2006-06-06 2016-02-09 Intra-Cellular Therapies, Inc. Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors
ES2411604T3 (es) 2006-11-13 2013-07-05 Intra-Cellular Therapies, Inc. Compuestos orgánicos
JP5837278B2 (ja) * 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規使用
US7901872B2 (en) 2007-05-21 2011-03-08 Macronix International Co., Ltd. Exposure process and photomask set used therein
BRPI0812909A2 (pt) * 2007-06-21 2014-12-09 Schering Corp Derivados de guanina policíclica e métodos de uso dos mesmos.
CN101969774A (zh) * 2007-12-06 2011-02-09 细胞内治疗公司 有机化合物
EP2939676A1 (en) 2007-12-06 2015-11-04 Intra-Cellular Therapies, Inc. Organic compounds
WO2009144548A1 (en) * 2008-05-28 2009-12-03 Glenmark Pharmaceuticals S.A. Imidazo [2,1-b] purine derivatives as trpa1 modulators
PE20110223A1 (es) 2008-06-10 2011-05-07 Abbvie Inc DERIVADOS DE PIRROLO[2,3-e][1,2,4]TRIAZOLO[4,3-a]PIRAZIN, COMO INHIBIDORES DE QUINASA
EA201170772A1 (ru) 2008-12-06 2012-03-30 Интра-Селлулар Терапиз, Инк. Органические соединения
US8536159B2 (en) 2008-12-06 2013-09-17 Intra-Cellular Therapies, Inc. Organic compounds
CN102223799A (zh) 2008-12-06 2011-10-19 细胞内治疗公司 有机化合物
EP2358204B1 (en) * 2008-12-06 2015-08-05 Intra-Cellular Therapies, Inc. 4,5,7,8-tetrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors.
AU2009322903A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
MX2011005935A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
WO2011016861A2 (en) 2009-08-05 2011-02-10 Intra-Cellular Therapies, Inc. Novel regulatory proteins and inhibitors
RS56317B1 (sr) 2009-12-01 2017-12-29 Abbvie Inc Nova triciklična jedinjenja
CA2781010A1 (en) 2009-12-01 2011-06-09 Abbott Laboratories Novel tricyclic compounds
WO2011153138A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
EP2575817A4 (en) 2010-05-31 2014-01-08 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
JP5894148B2 (ja) 2010-05-31 2016-03-23 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
CA2906640C (en) 2013-03-15 2021-07-20 Intra-Cellular Therapies, Inc. Substituted imidazo-[1,2-a]pyrazolo[4.3-e]pyrimidin-4[5h]-one compounds and pharmaceutical compositions and use therof as pde1 inhibitors
EP2968338B1 (en) 2013-03-15 2019-01-09 Intra-Cellular Therapies, Inc. Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
EP3091983B1 (en) 2014-01-08 2019-10-02 Intra-Cellular Therapies, Inc. Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor
DK3157926T3 (da) 2014-06-20 2019-08-19 Intra Cellular Therapies Inc Organiske forbindelser
WO2016022893A1 (en) 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
MX2017003646A (es) 2014-09-17 2017-07-13 Intra Cellular Therapies Inc Compuestos y metodos.
CN107205993B (zh) 2014-12-06 2021-03-09 细胞内治疗公司 有机化合物
WO2016090380A1 (en) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Organic compounds
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913993QA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規組成物および方法
JP7134168B6 (ja) 2016-09-12 2024-02-02 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規使用
EP3562828A1 (en) 2016-12-28 2019-11-06 Dart NeuroScience LLC Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
MX2020005447A (es) 2017-11-27 2020-12-03 Dart Neuroscience Llc Compuestos de furanopirimidina sustituida como inhibidores de pde1.
EP3746081A4 (en) 2018-01-31 2021-10-27 Intra-Cellular Therapies, Inc. INNOVATIVE USES

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7810946L (sv) * 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom
CH643260A5 (fr) * 1980-05-02 1984-05-30 Nestle Sa 1-allyl-3-butyl-8-methylxanthine, procede de preparation et utilisation dans un medicament.
US4663446A (en) * 1983-06-27 1987-05-05 Trustees Of The Univ. Of Massachusetts N2 (phenyl substituted) deoxy guanosine containing compounds
DE3324115A1 (de) * 1983-07-05 1985-01-17 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
DE3347290A1 (de) * 1983-12-28 1985-07-11 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-phenyl-imidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
DE3445299A1 (de) * 1984-12-12 1986-06-19 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CA2028235C (en) * 1989-10-20 1997-01-21 Fumio Suzuki Condensed purine derivatives
ZA914727B (en) * 1990-06-21 1992-03-25 Schering Corp Polycyclic guanine derivatives
DE4022314A1 (de) * 1990-07-13 1992-01-16 Boehringer Ingelheim Kg Verfahren zur herstellung von 2-chlor-1,7-dihydropurin-6-on und verfahren zu dessen reinigung
DE4035599A1 (de) * 1990-11-06 1992-05-07 Dresden Arzneimittel Neue 5-(phenoxyalkanoylamino)-uracile, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP3260037B2 (ja) * 1994-06-17 2002-02-25 松下電器産業株式会社 超音波ドプラ血流計

Also Published As

Publication number Publication date
AU681875B2 (en) 1997-09-11
HU9502464D0 (en) 1995-10-30
FI953981A0 (fi) 1995-08-24
CA2156918A1 (en) 1994-09-01
TW270118B (pt) 1996-02-11
HUT72640A (en) 1996-05-28
SG43809A1 (en) 1997-11-14
KR960701058A (ko) 1996-02-24
IL108754A0 (en) 1994-06-24
WO1994019351A1 (en) 1994-09-01
AU6268794A (en) 1994-09-14
JPH08507068A (ja) 1996-07-30
NZ262797A (en) 1997-08-22
EP0686157A1 (en) 1995-12-13
CN1118600A (zh) 1996-03-13
US5939419A (en) 1999-08-17

Similar Documents

Publication Publication Date Title
FI953981A (fi) 2-Bentsyyli-polysykliset guaniinijohdannaiset ja menetelmä niiden valmistamiseksi
FI941137A0 (fi) 2-debentsoyyli-2-asyylitaksolijohdannaisia ja menetelmiä niiden valmistamiseksi
FI903737A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten pentafluorietyyli-substituoitujen valiini- tai fenyylialaniinijohdannaisten valmistamiseksi
FI961599A0 (fi) 1N-alkyyli-N-aryylipyrimidiiniamiineja ja niiden johdannaisia
FI954718A0 (fi) Heterosykliset johdannaiset iskeemian ja vastaavien sairauksien hoitamiseksi
FI103666B1 (fi) Menetelmä bifenyylijohdannaisen valmistamiseksi
FI940769A (fi) Menetelmä 2-aminoatsolijohdannaisten valmistamiseksi
FI952324A (fi) Heterosykliset karbamaatit, menetelmä niiden valmistamiseksi ja lääkkeet
FI944713A (fi) 4-difenyylimetyylipiperidiinijohdannaisia ja menetelmä niiden valmistamiseksi
FI940775A (fi) alfa-fenyyli-isoseriinijohdannaisten valmistusmentelmä ja niiden käyttö
FI902727A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten kromaanijohdannaisten valmistamiseksi
FI903863A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten kromaanijohdannaisten valmistamiseksi
FI964310A0 (fi) Imidatsolijohdannainen ja menetelmä sen valmistamiseksi
FI942046A (fi) Polysykliset yhdisteet ja menetelmä niiden valmistamiseksi
FI944842A0 (fi) Fluoratut 4-aminoandrostadienonijohdannaiset ja menetelmä niiden valmistamiseksi
DE69119323D1 (de) Fluoräthylcamptothecinderivate
EE03027B1 (et) Meetod 8-klorokinolooni derivaatide valmistamiseks
FI940403A0 (fi) Elliptisiinijohdannainen ja menetelmä sen valmistamiseksi
FI924393A (fi) Bredbar produkt och foerfarande foer framstaellning av densamma
FI940551A (fi) Menetelmä fenyylibentsamidijohdannaisten valmistamiseksi
FI971964A0 (fi) Menetelmä 1-halo-3-trialkyylisilasnyylibentseenijohdannaisten valmistamiseksi
FI943660A (fi) Menetelmä 3-karbonyyliandrostadieeni-17-karboksamidien valmistamiseksi
FI940124A0 (fi) Palladiumin ja aromaattisten amiinijohdannaisten yhdisteitä ja menetelmä niiden valmistamiseksi
FI942139A0 (fi) Pyranyylisyaaniguanidiinijohdannaisten valmistuksessa käyttökelpoisia välituotteita ja menetelmiä niiden valmistamiseksi
FI932768A (fi) Farmaceutiska mjuka gelatinkapslar innehaollande lysinklonixinat och foerfarande foer framstaellning av dessa

Legal Events

Date Code Title Description
FD Application lapsed